CASI Pharmaceuticals, Inc. SEC filings CASIF

CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.

CASI Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
25-NSE Delisting notice Jun 23, 2026 —
D Filing Apr 28, 2026 —
NT 20-F Filing Apr 21, 2026 Dec 31, 2025
D Filing Feb 26, 2026 —
D Filing Jan 28, 2026 —
D Filing Jan 28, 2026 —
EFFECT Filing Dec 31, 2024 —
CORRESP Letter to the SEC Dec 30, 2024 —
UPLOAD Letter from the SEC Dec 26, 2024 —
EFFECT Filing Sep 3, 2024 —
CORRESP Letter to the SEC Aug 29, 2024 —
UPLOAD Letter from the SEC Aug 23, 2024 —
D Filing Jul 15, 2024 —
UPLOAD Letter from the SEC Jun 10, 2024 —
CORRESP Letter to the SEC May 30, 2024 —
UPLOAD Letter from the SEC May 22, 2024 —
EFFECT Filing May 10, 2024 —
CORRESP Letter to the SEC May 9, 2024 —
UPLOAD Letter from the SEC May 8, 2024 —
UPLOAD Letter from the SEC Sep 19, 2023 —
CORRESP Letter to the SEC Aug 25, 2023 —
UPLOAD Letter from the SEC Aug 14, 2023 —
8-A12B Form 8-a12b Mar 27, 2023 —
EFFECT Filing Feb 13, 2023 —
CORRESP Letter to the SEC Feb 9, 2023 —
UPLOAD Letter from the SEC Feb 8, 2023 —

Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CASIF (OTC)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Beijing, China
SEC filer status
Non-accelerated filer
SEC CIK
1962738
Former names
CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.